CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Evaluation of high insulin antibody response and related clinical outcomes in patients with T1DM or T2DM treated with LY2963016 and Lantus®
DOI 10.1055/s-0036-1580995
Bibliografische Angaben
Nachweis in CareLit
Autor:innenL Ilag, RK Pollom, T Costigan, J Zielonka, R Konrad, M Deeg, M Prince
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Objective: LY2963016 (LY IGlar) and Lantus® (IGlar) are insulin glargine products with similar efficacy and safety including insulin antibody responses that are low and similar between treatments. This evaluation assessed maximal antibody responses and relationships to clinical outcomes. Methods: Data were analyzed from the ELEMENT 1 (T1DM, 52-week, open-label, LY IGlar 265 patients, IGlar 267 patients) and ELEMENT…
Zitieren
Zitierempfehlung
L Ilag, RK Pollom, T Costigan, J Zielonka, R Konrad, M Deeg, M Prince (2016) Evaluation of high insulin antibody response and related clinical outcomes in patients with T1DM or T2DM treated with LY2963016 and Lantus®. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0036-1580995
Mit CareLit weiterarbeiten